Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

3,159 studies for “Roche”

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruiting
NCT03424005Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Metastatic Breast Cancer
United States, Australia, France, Germany, Israel +4 more
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's DiseaseRecruiting
NCT07717411Phase 3Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Alzheimer's Disease
United States, Canada, China, United Kingdom
Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsCompleted
NCT04896697Phase 1, Phase 2Updated Sep 10, 2026
Sponsor: Xilio Development, Inc.
Advanced Solid Tumor
United States
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast CancerActive Not Recruiting
NCT05852691Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Australia, Brazil, Czechia +11 more
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionCompleted
NCT04661150Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive Not Recruiting
NCT04931342Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Ovarian Cancer
United States, Australia, Canada, Czechia, France +8 more
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruiting
NCT07670416Phase 3Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Obesity · Overweight · Type 2 Diabetes Mellitus (T2DM)
China
A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)Recruiting
NCT07161258Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Relapsing Multiple Sclerosis
Argentina, Brazil, Mexico, Poland, Portugal +2 more
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Completed
NCT02546700Phase 2Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease
United States, Argentina, Bulgaria, Canada, Denmark +4 more
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene TherapyRecruiting
NCT05861999Phase 4Updated Sep 10, 2026
Sponsor: Hoffmann-La Roche
Muscular Atrophy, Spinal
United States, Germany, Israel, Poland, Qatar +1 more
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related ComorbidityActive Not Recruiting
NCT06965413Phase 2Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Obesity · Overweight · Overweight With One Weight Related Comorbidity
United States, Poland, Spain, United Kingdom
A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)Active Not Recruiting
NCT06128564Phase 2Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Duchenne Muscular Dystrophy
Belgium, France, Germany, Italy, Spain +1 more
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)Active Not Recruiting
NCT04958265Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Atypical Hemolytic Uremic Syndrome
United States, Belgium, Brazil, Canada, China +5 more
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)Recruiting
NCT07541170Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Non-small Cell Lung Cancer
United States, Argentina, Brazil, Hong Kong, Italy +1 more
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung CancerActive Not Recruiting
NCT05091567Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Small-Cell Lung Cancer
United States, Belgium, Germany, Greece, Hungary +8 more
A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia ARecruiting
NCT07416526Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Hemophilia A
United States, Argentina, Brazil, Denmark, France +10 more
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)Active Not Recruiting
NCT07234942Phase 1Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Alzheimer's Disease
Canada, Netherlands, Spain, Sweden, United Kingdom
A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or OverweightNot Yet Recruiting
NCT07589686Phase 2Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Obesity or Overweight
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular AtrophyActive Not Recruiting
NCT05115110Phase 2, Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Spinal Muscular Atrophy (SMA)
United States, Australia, Belgium, Canada, Croatia +7 more
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseRecruiting
NCT06998524Phase 3Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Von Willebrand Disease, Type 3
United States, Belgium, Canada, Colombia, France +9 more
A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult ParticipantsActive Not Recruiting
NCT06982131Phase 1Updated Sep 9, 2026
Sponsor: Hoffmann-La Roche
Overweight · Obesity
Netherlands
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese ParticipantsRecruiting
NCT07626515Phase 1Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Healthy Participants
China
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruiting
NCT05789082Phase 1, Phase 2Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +13 more
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruiting
NCT06793215Phase 3Updated Sep 8, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer · KRAS G12C Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +23 more
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruiting
NCT07100106Phase 1, Phase 2Updated Sep 8, 2026
Sponsor: Genentech, Inc.
Breast Cancer
United States, Australia, Brazil, Canada, China +5 more

3,159 studies found